Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Updated HSBC on June 5 Dr. Reddy’s Laboratories Limited (NYSE:RDY) Increasing the purchased, pricing target to INR1,235, referring to an optimistic worldview in terms of earnings and strong market stops.
An employee in the biofarmaceutical object packing an active pharmaceutical part of an active pharmaceutical part.
Updated calculations for HSBC’s FY2026 FY2028 Please consider the variable market tide for Semaglutide and GrevlimID. Analysts expect FY2026 to be presented in Canada, Brazil and India at the beginning of FY2027, which is a starting assumption in Canada.
Analysts, Dr. Reddy’s Laboratories Limited (NYSE: RDY) ‘s GrevlimID, noting the growing competition, reviewed FY2026 sales figures. The EPS forecast for the 5.1% decrease in EPS estimate for FY2026, FY2027 and FY2028 increased from 12% to 13%.
According to HSBC analysts, the expected increase in the sale of semaglutide will strengthen Dr. Reddi’s earnings. HSBC increased a new price target (ADR) for the American Deposit Receipts (ADR), as well as $ 14.44 for $ 16.90.
Dr. Reddy’s Laboratories Limited (NYSE: RDY) is a Global Pharma company that develops both branded and common medications for both Indian and extensive health conditions. The company operates through global generations, pharmaceutical services and active ingredients (PSAI) and other segments.
If we accept the potential of RDY as an investment, some of the AI shares of our belief are losing more to give rise to higher income and restrict risk. If you are looking for an extremely cheaper AI exchange with a great benefit of Trump Tariffs and OnShoring, please see our free report The best short-term EU reserve.
Read the next: 10 borrowed debt free of these Penny shares and 10 non-stop shares that can double your money.
Disclosure: No.
